Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs
Clinical and Experimental Pharmacology and Physiology · 2025-09 · 52 (9)
DOI: 10.1111/1440-1681.70064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 05.08.2025. Verfasst von Yulin Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Proteolysis, Antineoplastic Agents, Neoplasms, Neoplasm Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Molecular glues have emerged as a novel class of targeted protein degraders with broad potential in cancer therapy. By inducing proximity between E3 ubiquitin ligases and oncogenic proteins, these agents activate the ubiquitin–proteasome system to drive selective protein degradation. This review systematically explores the application strategies of molecular glues in the targeted degradation of cancer‐related proteins located in different subcellular compartments: nuclear cancer proteins (Ikaros, Helios, Aiolos, B‐cell lymphoma 6 protein, cyclin K, RNA binding motif protein 39) and cytoplasmic cancer proteins (β‐catenin, casein kinase 1α, G1 to S phase transition factor 1). Additionally, this work discusses current challenges and optimisation strategies, offering new perspectives for the development of precision anti‐cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shandong Second Medical University, Weifang, China.
- School of Medicine, Shanghai University, Shanghai, China.
- Third Affiliated Hospital of Naval Medical University, Shanghai, China.
- Shanghai Engineering Research Center of Organ Repair, Shanghai, China.
- Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai, China.
ORCID-Profile: Honggang Hu
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Shen, Y., Wen, W., Chen, L., Zhang, N., Cong, W., & Hu, H. (2025). Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs. Clinical and Experimental Pharmacology and Physiology, 52(9). https://doi.org/10.1111/1440-1681.70064
Vancouver
Shen Y, Wen W, Chen L, Zhang N, Cong W, Hu H. Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs. Clinical and Experimental Pharmacology and Physiology. 2025;52(9). doi:10.1111/1440-1681.70064
BibTeX
@article{Shen2025,
author = {Shen, Yulin and Wen, Wen and Chen, Luoyang and Zhang, Nan and Cong, Wei and Hu, Honggang},
title = {Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2025},
volume = {52},
number = {9},
doi = {10.1111/1440-1681.70064}
}
EUVIMED